Log In
BCIQ
Print this Print this
 

nemolizumab (CIM331)

  Manage Alerts
Collapse Summary General Information
Company Chugai Pharmaceutical Co. Ltd.
DescriptionHumanized mAb against IL-31 receptor
Molecular Target Interleukin-31 (IL-31) receptor
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/28/2016

Undisclosed

Undisclosed

Undisclosed

07/20/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today